Ukraine's pharmaceuticals: from dependence to endogenous development

O. Salikhova, D. Honcharenko
{"title":"Ukraine's pharmaceuticals: from dependence to endogenous development","authors":"O. Salikhova, D. Honcharenko","doi":"10.15407/ECONFORECAST2020.04.005","DOIUrl":null,"url":null,"abstract":"The article substantiates various theoretical and applied principles of developing high-tech pharmaceutical industries (HTPI). It is established that the key problem of developing countries in this area is the dependence on resources and markets of developed countries, while the involvement of advanced foreign technologies can be a catalyst for increasing the technological potential of host countries (subject to the availability of proper knowledge and human capital, changes in the institutional environment, and improved the framework conditions for innovation). In the context of the development of HTPI, the author shows the importance of the network nature of the acquisition by pharmaceutical companies of sustainable competitive advantages based on resources that are difficult to simulate or replace. It is substantiated that networks built with local research institutions, higher education institutions, and research units of other companies, give pharmaceutical manufacturers the opportunity to access complementary assets and become their specific resource, which provides unique competitive advantages. The author reveals various methodological and statistical features of the categorization of industries by the level of technology in the conditions of globalization. It is substantiated that the current low value of the ratio of research and development (R&D) to value-added generated by pharmaceuticals of individual countries is not a sign of the industry’s low technological level, as the current revenues are the result of long-term R&D and harmonization procedures for launching new drugs with lags of 10-15 years. A new tool for the study of international trade in high-tech pharmaceuticals is proposed, whose peculiar feature consists in the categorization of nomenclature items by end use; the List of high-tech medical and pharmaceutical intermediate goods is formulated (in accordance with SITC Rev.4 and UKT FEA); the following indicators are proposed: the coefficient of import dependence of pharmaceutical production, the coefficient of \"purified\" exports of pharmaceutical products and the coefficient of imports coverage with HTPI output, and the formulas for their calculation are provided. The author's approach is the first to create the opportunity to assess the scale of costs and the dependence of the pharmaceutical industry on imported components that embody advanced technologies and are the industrial supplies for HTPI. It was found that in Ukraine the share of foreign intermediate high-tech goods in the consumption of the industry reaches 82.2%; the industry, working on imported substances, produces mainly products for the domestic market, without earning foreign currency, even to cover the cost of purchasing the necessary ingredients; manufacturers do not rely on synthesized chemical products of domestic production, primarily due to the fact that the products of the chemical industry for the needs of pharmaceuticals in Ukraine are virtually non-existent; and the increase in output depends on foreign technologies and intermediate goods. It is substantiated that Ukraine’s pharmaceutical industry is critically dependent on imported supplies to ensure the smooth operation of enterprises and the healthcare industry. Key endogenous barriers that hinder the development of HTPI have been identified, including problems in the training of specialists and a lack of scientists whose competencies would contribute to solving the problems of endogenous development of the industry; lack of state aid to business entities for research, and technological and innovative activities; lack of own funds to increase expenditures on R&D and implementation of large-scale investment and innovation projects; and lack of cheap loans, due to which Ukrainian pharmaceutical manufacturers find themselves in unequal conditions compared to foreign competitors. Conceptual bases of HTPI development in Ukraine are proposed; justified the expediency of legal changes, definition of strategic priorities and introduction of measures of development of HTPI in Ukraine based on the comprehensive approach, which will cover creation and development of pharmaceutical ingredients for medicines (chemical and biotechnological goods), medical products, fillers, packing materials, machinery and equipment for pharmaceuticals to help reduce the dependence on foreign technologies, and to increase the level of production localization, employment and revenues to the budgets of all levels.","PeriodicalId":212761,"journal":{"name":"Economy and Forecasting","volume":"26 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2020-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Economy and Forecasting","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15407/ECONFORECAST2020.04.005","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 4

Abstract

The article substantiates various theoretical and applied principles of developing high-tech pharmaceutical industries (HTPI). It is established that the key problem of developing countries in this area is the dependence on resources and markets of developed countries, while the involvement of advanced foreign technologies can be a catalyst for increasing the technological potential of host countries (subject to the availability of proper knowledge and human capital, changes in the institutional environment, and improved the framework conditions for innovation). In the context of the development of HTPI, the author shows the importance of the network nature of the acquisition by pharmaceutical companies of sustainable competitive advantages based on resources that are difficult to simulate or replace. It is substantiated that networks built with local research institutions, higher education institutions, and research units of other companies, give pharmaceutical manufacturers the opportunity to access complementary assets and become their specific resource, which provides unique competitive advantages. The author reveals various methodological and statistical features of the categorization of industries by the level of technology in the conditions of globalization. It is substantiated that the current low value of the ratio of research and development (R&D) to value-added generated by pharmaceuticals of individual countries is not a sign of the industry’s low technological level, as the current revenues are the result of long-term R&D and harmonization procedures for launching new drugs with lags of 10-15 years. A new tool for the study of international trade in high-tech pharmaceuticals is proposed, whose peculiar feature consists in the categorization of nomenclature items by end use; the List of high-tech medical and pharmaceutical intermediate goods is formulated (in accordance with SITC Rev.4 and UKT FEA); the following indicators are proposed: the coefficient of import dependence of pharmaceutical production, the coefficient of "purified" exports of pharmaceutical products and the coefficient of imports coverage with HTPI output, and the formulas for their calculation are provided. The author's approach is the first to create the opportunity to assess the scale of costs and the dependence of the pharmaceutical industry on imported components that embody advanced technologies and are the industrial supplies for HTPI. It was found that in Ukraine the share of foreign intermediate high-tech goods in the consumption of the industry reaches 82.2%; the industry, working on imported substances, produces mainly products for the domestic market, without earning foreign currency, even to cover the cost of purchasing the necessary ingredients; manufacturers do not rely on synthesized chemical products of domestic production, primarily due to the fact that the products of the chemical industry for the needs of pharmaceuticals in Ukraine are virtually non-existent; and the increase in output depends on foreign technologies and intermediate goods. It is substantiated that Ukraine’s pharmaceutical industry is critically dependent on imported supplies to ensure the smooth operation of enterprises and the healthcare industry. Key endogenous barriers that hinder the development of HTPI have been identified, including problems in the training of specialists and a lack of scientists whose competencies would contribute to solving the problems of endogenous development of the industry; lack of state aid to business entities for research, and technological and innovative activities; lack of own funds to increase expenditures on R&D and implementation of large-scale investment and innovation projects; and lack of cheap loans, due to which Ukrainian pharmaceutical manufacturers find themselves in unequal conditions compared to foreign competitors. Conceptual bases of HTPI development in Ukraine are proposed; justified the expediency of legal changes, definition of strategic priorities and introduction of measures of development of HTPI in Ukraine based on the comprehensive approach, which will cover creation and development of pharmaceutical ingredients for medicines (chemical and biotechnological goods), medical products, fillers, packing materials, machinery and equipment for pharmaceuticals to help reduce the dependence on foreign technologies, and to increase the level of production localization, employment and revenues to the budgets of all levels.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
乌克兰医药:从依赖到内生发展
本文阐述了发展高新技术医药产业的各种理论和应用原则。可以确定的是,发展中国家在这一领域的关键问题是依赖发达国家的资源和市场,而外国先进技术的参与可以成为增加东道国技术潜力的催化剂(取决于是否有适当的知识和人力资本、体制环境的变化和创新的框架条件的改善)。在HTPI发展的背景下,作者展示了制药公司基于难以模拟或替代的资源获取可持续竞争优势的网络性质的重要性。研究表明,与当地研究机构、高等教育机构和其他公司的研究单位建立网络,使制药企业有机会获得互补资产,并成为其特定资源,这提供了独特的竞争优势。作者揭示了全球化条件下按技术水平进行产业分类的各种方法和统计特征。研究表明,目前各国药品的研发(R&D)与附加值之比较低,并不是该行业技术水平低的标志,因为目前的收入是长期研发和新药上市协调程序的结果,滞后10-15年。提出了一种研究高技术药品国际贸易的新工具,其特点是按最终用途对命名项目进行分类;制定高技术医药中间体产品清单(按照SITC Rev.4和UKT FEA);提出了药品生产进口依赖系数、药品“纯化”出口系数和进口覆盖系数,并给出了计算公式。作者的方法是第一个创造机会来评估成本的规模和制药业对进口组件的依赖,这些组件体现了先进的技术,是HTPI的工业供应。研究发现,在乌克兰,国外中间高技术产品在工业消费中的份额达到82.2%;从事进口物质的工业主要为国内市场生产产品,没有赚取外汇,甚至不足以支付购买必要成分的费用;制造商不依赖国内生产的合成化学产品,主要是因为满足乌克兰药品需求的化学工业产品几乎不存在;而产出的增长依赖于外国技术和中间产品。事实证明,乌克兰的制药业严重依赖进口供应品,以确保企业和医疗保健行业的顺利运作。已查明阻碍HTPI发展的主要内生障碍,包括培训专家方面的问题和缺乏具有能力有助于解决工业内生发展问题的科学家;国家对企业的研究、技术和创新活动缺乏援助;缺乏自有资金,无法加大研发支出和实施大型投资创新项目;以及缺乏廉价贷款,因此乌克兰制药商发现自己与外国竞争对手处于不平等的条件。提出了乌克兰HTPI发展的概念基础;说明修改法律、确定战略优先事项和在乌克兰采取基于综合办法的HTPI发展措施的适宜性,其中将包括药品(化学和生物技术产品)、医疗产品、填料、包装材料、药品机械和设备的创造和开发,以帮助减少对外国技术的依赖;提高生产本地化水平,增加各级预算的就业和收入。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Science and innovation in Ukraine: approaches to policy making in times of war REGULATION OF UKRAINE’S COMMODITY MARKETS IN CONDITIONS OF EMERGENCY AND MARTIAL LAW A RHYMED CHRONICLE OF THE WAR UKRAINE’S POST-WAR ECONOMY: INTERNATIONAL AID AND GROWTH POLICY STRATEGIES OF ECONOMIC STABILITY IN UNSTABLE ENVIRONMENT
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1